
## Brady Sillman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11830089/publications.pdf Version: 2024-02-01



**Β**ρλην **S**ιιι ΜλΝ

#	Article	IF	CITATIONS
1	Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nature Communications, 2022, 13, .	12.8	21
2	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications, 2021, 12, 3453.	12.8	29
3	Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice. Journal of NeuroImmune Pharmacology, 2021, 16, 796-805.	4.1	7
4	A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials, 2020, 19, 910-920.	27.5	66
5	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, 2753.	12.8	222
6	Creation of a long-acting rilpivirine prodrug nanoformulation. Journal of Controlled Release, 2019, 311-312, 201-211.	9.9	22
7	Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 2018, 9, 443.	12.8	101
8	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	30
9	Long-acting slow effective release antiretroviral therapy. Expert Opinion on Drug Delivery, 2017, 14, 1281-1291.	5.0	53
10	Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. Journal of Clinical Investigation, 2017, 127, 857-873.	8.2	44